findmyKOL

Joseph Mace, MD

Basic profile

Medical Oncology

ORCIDNone on fileNPI
RegionSt Petersburg, FL · SoutheastSpecialtyMedical OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH funding2004–2005Why? →

Joseph Mace is an Oncology physician. OpenAlex indexes 41 publications with 2,812 citations (h-index 14).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
41publications

Distinct works indexed by OpenAlex.

2,812citations

Total citations across indexed works.

14h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
68companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2004–2005

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

725 6th Ave S Ste 2200
St Petersburg, FL 337014553

Telephone

727-821-0017

Provider last certified this registry record 8 Jan 2026.

View the NPPES registry record

Industry payments

68 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    76.4%
    Parenteral Iron Replacement68.6%
    Iron sucrose100%
    Part B, office-administered41 patients
    Erythropoiesis-stimulating Agent7.5%
    Epoetin alfa100%
    Part B, office-administered20 patients

    + 2 more classes in this area

  • Musculoskeletal

    10.8%
    RANK Ligand Inhibitor10.5%
    Denosumab100%
    Part B, office-administered26 patients
    Bisphosphonate0.2%
    Zoledronic acid100%
    Part B, office-administered13 patients

    + 1 more class in this area

  • Anti-infectives

    5.4%
    Human Immunoglobulin G5.2%
    Immune globulin100%
    Part B, office-administered11 patients
    Penicillins with extended spectrum0.1%
    Amoxicillin-Clavulanate Potass100%
    Part D27 patients

    + 2 more classes in this area

Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20042005 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”